Phase III Trial Adding Vincristine-Topotecan-Cyclophosphamide to the Initial Treatment of Patients With Nonmetastatic Ewing Sarcoma: A Children's Oncology Group Report.
Patrick J LeaveyNadia N Issa LaackMark D KrailoAllen BuxtonRobert Lor RandallSteven G DuBoisDamon R ReedHolcombe E GrierDouglas S HawkinsBruce PawelHelen Ruth NadelRichard B WomerG Douglas LetsonMark BernsteinKenneth BrownAlexis MaciejPaul ChubaAtif A AhmedDaniel J IndelicatoDian WangNeyssa M MarinaRichard G GorlickKatherine A JanewayLeo MascarenhasPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
While VTC added to five-drug interval compressed chemotherapy did not improve survival, these outcomes represent the best survival estimates to date for patients with previously untreated nonmetastatic Ewing sarcoma.
Keyphrases
- phase iii
- open label
- clinical trial
- phase ii
- double blind
- placebo controlled
- free survival
- young adults
- palliative care
- high dose
- study protocol
- emergency department
- type diabetes
- randomized controlled trial
- adipose tissue
- squamous cell carcinoma
- adverse drug
- replacement therapy
- drug induced
- skeletal muscle
- chemotherapy induced
- weight loss